Improving the sensitivity and specificity of a bioanalytical assay for the measurement of certolizumab pegol

Bioanalysis

Volumn 9, Issue 16, 2017, Pages 1217-1226

  Smeraglia, John ^a   Silva, John Paul ^a   Jones, Kieran ^a  

^a UCB PHARMA   (Belgium)

Author keywords

certolizumab pegol; electrochemiluminescence; ELISA; immunoassay; placental transfer; validation

Indexed keywords

CERTOLIZUMAB PEGOL;

ACCURACY; ANALYTICAL PARAMETERS; BIOANALYTICAL ASSAY; BIOASSAY; CALIBRATION; CHEMICAL PHENOMENA; CONTROLLED STUDY; DILUTION LINEARITY; DRUG BLOOD LEVEL; DRUG STABILITY; ELECTROCHEMILUMINESCENCE IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOASSAY; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MATRIX INTERFERENCE; REVIEW; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS; BLOOD; BLOOD ANALYSIS; CHEMISTRY; FETUS BLOOD; INFANT; PROCEDURES;

BLOOD CHEMICAL ANALYSIS; CALIBRATION; CERTOLIZUMAB PEGOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FETAL BLOOD; HUMANS; INFANT; LIMIT OF DETECTION;

EID: 85028553821     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio-2017-0124     Document Type: Review

References (28)

1. Melmed G, Targan SR, Yasothan U, Hanicq D, Kirkpatrick P. Certolizumab pegol. Nat. Rev. Drug Discov. 7, 641-642 (2008).
2. European Medicines Agency. Annex 1: Summary of product characteristics (Cimzia) (2017). www.ema.europa.eu
3. European Medicines Agency. CIMZIA European public assessment report (2015). www.ema.europa.eu
4. Mease P, Fleischmann R, Deodhar AA et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase III double-blind randomised placebo-controlled study (RAPID-PsA). Ann. Rheum. Dis. 73, 48-55 (2014).
5. van der Heijde D, Fleischmann R, Wollenhaupt J et al. Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week Phase III double-blind randomised placebo-controlled study of certolizumab pegol. Ann. Rheum. Dis. 73, 233-237 (2014).
6. Reich K, Ortonne JP, Gottlieb AB et al. Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab′ certolizumab pegol: results of a Phase II randomized, placebo-controlled trial with a re-treatment extension. Br. J. Dermatol. 167, 180-190 (2012).
7. Schreiber S. Certolizumab pegol for the treatment of Crohn's disease. Ther. Adv. Gastroenterol. 4, 375-389 (2011).
8. Landewé R, Braun J, Deodhar AA et al. Effcacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24 week results of a double-blind randomized placebo-controlled Phase III study. Ann. Rheum. Dis. 73, 39-47 (2014).
9. Broms G, Granath F, Linder M et al. Birth outcomes in women with infammatory bowel disease: effects of disease activity and drug exposure. Infamm. Bowel Dis. 20, 1091-1098 (2014).
10. de Man YA, Hazes JM, van der Heide H et al. Association of higher rheumatoid arthritis disease activity during pregnancy with lower birth weight: results of a national prospective study. Arthritis Rheum. 60, 3196-3206 (2009).
11. Mahadevan U, Sandborn WJ, Li DK et al. Pregnancy outcomes in women with infammatory bowel disease: a large community-based study from Northern California. Gastroenterology 133, 1106-1112 (2007).
12. Norgaard M, Larsson H, Pedersen L et al. Rheumatoid arthritis and birth outcomes: a Danish and Swedish nationwide prevalence study. J. Intern. Med. 268, 329-337 (2010).
13. Jakobsson GL, Stephansson O, Askling J et al. Pregnancy outcomes in patients with ankylosing spondylitis: a nationwide register study. Ann. Rheum. Dis. 75, 1838-1842 (2016).
14. Gisbert JP, Chaparro M. Safety of anti-TNF agents during pregnancy and breastfeeding in women with infammatory bowel disease. Am. J. Gastroenterol. 108, 1426-1438 (2013).
15. Hyrich KL, Verstappen SM. Biologic therapies and pregnancy: the story so far. Rheumatology (Oxford) 53, 1377-1385 (2014).
16. Hazes JM, Coulie PG, Geenen V et al. Rheumatoid arthritis and pregnancy: evolution of disease activity and pathophysiological considerations for drug use. Rheumatology (Oxford) 50, 1955-1968 (2011).
17. Maidji E, McDonagh S, Genbacev O, Tabata T, Pereira L. Maternal antibodies enhance or prevent cytomegalovirus infection in the placenta by neonatal Fc receptor-mediated transcytosis. Am. J. Pathol. 168(4), 1210-1226 (2006).
18. Simister N. Placental transport of Immunoglobulin G. Vaccine 21(24), 3365-3369 (2003).
19. Mahadevan U, Wolf DC, Dubinsky M et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with infammatory bowel disease. Clin. Gastroenterol. Hepatol. 11(3), e286-e224 (2013).
20. Förger F, Zbinden A, Villiger PM. Certolizumab treatment during late pregnancy in patients with rheumatic diseases: low drug levels in cord blood but possible risk for maternal infections. A case series of 13 patients. Joint Bone Spine 83(3), 341-343 (2016).
21. Porter C, Armstrong-Fisher S, Kopotsha T et al. Certolizumab pegol does not bind the neonatal Fc receptor (FcRn): consequences for FcRn-mediated in vitro transcytosis and ex vivo human placental transfer. J. Reprod. Immunol. 116, 7-12 (2016).
22. Meso Scale Discovery. Singleplex and Multiplex Assay List (2017). www.mesoscale.com/∼/media/fles/handouts/assaylist.pdf
23. Wade J, Parker G, Kosutic G et al. Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn's disease. J. Clin. Pharmacol. 55(8), 866-874 (2015).
24. DeSilva B, Smith W, Weiner R et al. Recommendations for the bioanalytical method validation of ligand binding assays to support pharmacokinetic assessments for macromolecules. Pharm. Res. 20(11), 1885-1990 (2003).
25. Shah VP, Midha KK, Findlay JW et al. Bioanalytical method validation: a revisit with a decade of progress. Pharm. Res. 17(17), 1551-1557 (2000).
26. Viswanathan CT, Bansal S, Booth B et al. Quantitative bioanalytical method and implementation: best practices for chromatographic and ligand binding assays. Pharm. Res. 24(10), 1962-1973 (2007).
27. Guideline on Bioanalytical Method Validation (EMEA/CHMP/EWP/192217/2009 Rev.1 Corr.2). European Medicines Agency, London, UK (2011). www.ema.europa.eu
28. Guidance for Industry: Bioanalytical Method Validation. Center for Drug Evaluation and Research, US FDA, MD, USA (2013). www.fda.gov